Online inquiry

IVTScrip™ mRNA-Anti-MAPT, ABBV-8E12(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ1094MR)

This product GTTS-WQ1094MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 1 & 5-Methyl-CTP & Pseudo-UTP. It ecodes the monoclonal antibody that targets MAPT gene. The antibody can be applied in Progressive supranuclear palsy (PSP) research.
Specifications
Product type mRNA
Modified bases 5-Methyl-CTP & Pseudo-UTP
5' Cap Cap 1
Species Chimeric
RefSeq NM_001123066.4
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 4137
UniProt ID P10636
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-MAPT, ABBV-8E12(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) (GTTS-WQ1094MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ2285MR IVTScrip™ mRNA-Anti-C5, ALXN1007(Cap 0, 2-Thio-UTP, 30 nt-poly(A)) mRNA ALXN1007
GTTS-WQ4543MR IVTScrip™ mRNA-Anti-PDCD1, BMS-936558(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA BMS-936558
GTTS-WQ9980MR IVTScrip™ mRNA-Anti-env, KD-247(Cap 0, 2-Thio-UTP, 120 nt-poly(A)) mRNA KD-247
GTTS-WQ6982MR IVTScrip™ mRNA-Anti-pagA, ETI-204(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA ETI-204
GTTS-WQ14709MR IVTScrip™ mRNA-Anti-SELP, SEG101(Cap 1, Pseudo-UTP, 30 nt-poly(A)) mRNA SEG101
GTTS-WQ1728MR IVTScrip™ mRNA-Anti-CD40, ADC-1013(Cap 0, Pseudo-UTP, 30 nt-poly(A)) mRNA ADC-1013
GTTS-WQ11991MR IVTScrip™ mRNA-Anti-ERBB3, MM-121(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA MM-121
GTTS-WQ1238MR IVTScrip™ mRNA-Anti-DLL4&VEGFA, ABT-165(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA ABT-165
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW